NKTR-255 联合 CD19-22 CAR-T 细胞疗法治疗难治性 B 细胞急性淋巴细胞白血病的 1 期临床试验
A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia.
肿瘤细胞治疗研究
FRONTIER PAPERS
近 5 年肿瘤细胞治疗领域的研究论文。默认按评分排序(权威性 + 新鲜度)。
A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia.
Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial.
CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia
共 3 条
MEMBER ACCOUNT
登录成功会直接打开下一页。